Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 02:37 ET | Source: Sosei Group Corporation

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders

TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero BioPhase 1...
December 20, 2022 19:01 ET | Source: Sosei Group Corporation

Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10...
December 20, 2022 01:30 ET | Source: Sosei Group Corporation

Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference

TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41st...
December 15, 2022 19:01 ET | Source: Sosei Group Corporation

Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases

New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
December 13, 2022 01:30 ET | Source: Sosei Group Corporation

Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases

TOKYO and CAMBRIDGE, United Kingdom, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused...
December 08, 2022 01:30 ET | Source: Sosei Group Corporation

Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant...
November 11, 2022 01:30 ET | Source: Sosei Group Corporation

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022

TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
November 09, 2022 03:00 ET | Source: Sosei Group Corporation

Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022

TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK...
October 27, 2022 19:05 ET | Source: Sosei Group Corporation

Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”;...
September 27, 2022 02:30 ET | Source: Sosei Group Corporation

Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum

TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The...